Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 83

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 2
Chunk 83
---
 -   -   -   8,117 Reversal of expected credit losses  -   69,759   -   552,663 Others  3,477   74,089   210   18,963 TOTAL OTHER INCOME  28,569   180,892   37,364   692,741                  OPERATING EXPENSES                Sales and marketing  (28,424)  (559,541)  (23,011)  (103,257)Research and development  (12,557)  -   (8,198)  - General and administrative  (149,164)  (161,591)  (73,154)  (121,741)Fair value loss on investments in equity securities  -   (51,002)  -   (56,136)TOTAL OPERATING EXPENSES  (190,145)  (772,134)  (104,363)  (281,134)                 (LOSS)/PROFIT FROM OPERATIONS  (160,835)  (223,961)  (63,856)  697,184                  FINANCE COSTS  (3,273)  (1,599)  (2,646)  (1,746)                 (LOSS)/PROFIT BEFORE TAX  (164,108)  (225,560)  (66,502)  695,438                  Tax expense  -   -   -   (55,584)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS $(164,108) $(225,560) $(66,502) $639,854 

 37Table of Contents

Revenue. For the current quarter ended June 30, 2025, we had total revenue of $2,260,253, an increase of 14.5% as compared to total revenue of $1,974,564 for the same quarter in the previous year.

MRNA Scientific contributed $3,466 (0.2%) of the total revenue for the current quarter ended June 30, 2025, as compared to revenue